Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Respiratory Tract Infections in adults with risk of recurrence after standard treatment with bacterial lysates Paspat 3 mg tablets, over an observation period of six months. - ACASP

开始日期2016-07-06

申办/合作机构

Daiichi Sankyo Italia SpA

100 项与 LW-50020 相关的临床结果

登录后查看更多信息

100 项与 LW-50020 相关的转化医学

登录后查看更多信息

100 项与 LW-50020 相关的专利（医药）

登录后查看更多信息

项与 LW-50020 相关的文献（医药）

2024-01-01·Journal of Immunology Research

Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer

Review

作者: Ulett, Glen C ; Rahman, Md Mijanur ; Grice, I Darren ; Wei, Ming Q

Antigenic cell fragments, pathogen‐associated molecular patterns, and other immunostimulants in bacterial lysates or extracts may induce local and systemic immune responses in specific and nonspecific paradigms. Based on current knowledge, this review aimed to determine whether bacterial lysate has comparable functions in infectious diseases and cancer treatment. In infectious diseases, including respiratory and urinary tract infections, immune system activation by bacterial lysate can identify and combat pathogens. Commercially available bacterial lysates, including OM‐85, Ismigen, Lantigen B, and LW 50020, were effective in children and adults in treating respiratory tract infections, chronic obstructive pulmonary disease, rhinitis, and rhinosinusitis with varying degrees of success. Moreover, OM‐89, Uromune, Urovac, Urivac, and ExPEC4V showed therapeutic benefits in controlling urinary tract infections in adults, especially women. Bacterial lysate‐based therapeutics are safe, well‐tolerated, and have few side effects, making them a good alternative for infectious disease management. Furthermore, a nonspecific immunomodulation by bacterial lysates may stimulate innate immunity, benefiting cancer treatment. “Coley’s vaccine” has been used to treat sarcomas, carcinomas, lymphomas, melanomas, and myelomas with varying outcomes. Later, several similar bacterial lysate‐based therapeutics have been developed to treat cancers, including bladder cancer, non‐small cell lung cancer, and myeloma; among them, BCG for in situ bladder cancer is well‐known. Proinflammatory cytokines, including IL‐1, IL‐6, IL‐12, and TNF‐α, may activate bacterial antigen‐specific adaptive responses that could restore tumor antigen recognition and response by tumor‐specific type 1 helper cells and cytotoxic T cells; therefore, bacterial lysates are worth investigating as a vaccination adjuvants or add‐on therapies for several cancers.

2018-10-31·Otolaryngologia Polska

Bacterial lysates in the prevention of respiratory tract infections

Review

作者: Zielnik-Jurkiewicz, Beata ; Jurkiewicz, Dariusz

Bacterial lysates stimulate the general immunity of the body in a non-specific way. They act on non-specific defense mechanisms, leading to an increase in type A antibody in mucous membranes, phagocytic activity and INF-ƴ production. They can also stimulate the production of specific antibodies against the bacterial antigens that make up the preparation. The oral immunomodulatory preparations with the best documented clinical efficacy available on the Polish market are Ismigen, Broncho-Vaxom, Ribomunyl and Luivac. They are all lysates of bacterial strains that most often cause respiratory tract infections. In many clinical trials, oral bacterial lysates have been shown to minimize the risk of recurrent respiratory infections in children and adults and reduce the need for antibiotics.

2010-09-01·Vnitrni lekarstvi

[Immunotherapy and long-term chemoprophylaxis in prevention of recurrent urinary infections in women].

Article

作者: Hromec, J ; Gábrisová, Z ; Tahotný, R ; Krcméry, S

In clinical practice, management of urinary infections is a frequent task. Long-term prophylactic administration of small-dose chemotherapy had been shown to prevent recurrent urinary infections. Recently, an interest increases in applying immunotherapy in this indication. The authors compare immunomodulators Urovaxom and Luivac as part ofa combined immunotherapy and chemoprophylaxis regimens with small doses of fluorochinolones over 12 months in women with recurrent urinary infections. This treatment statistically significantly decreases occurrence of relapses and has been relatively well-tolerated. Unlike previous studies, we managed to isolate resistant strains producing the so-called extended-spectrum beta-lactamases (ESBL) and this may provide a signal for revision of some therapeutic approaches. In line with international recommendations, we prefer immunotherapy as comparably effective but safer treatment modality than the long-term chemoprophylaxis with fluorochinolones.

100 项与 LW-50020 相关的药物交易

登录后查看更多信息